Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 1,800 shares of the stock in a transaction on Friday, November 18th. The shares were purchased at an average price of $10.38 per share, with a total value of $18,684.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $31,855,711.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, November 21st, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The stock was purchased at an average price of $10.41 per share, with a total value of $37,476.00.
  • On Wednesday, November 16th, Phillip Md Et Al Frost bought 4,300 shares of Opko Health stock. The stock was purchased at an average price of $10.13 per share, with a total value of $43,559.00.
  • On Friday, November 11th, Phillip Md Et Al Frost bought 14,600 shares of Opko Health stock. The stock was purchased at an average price of $9.46 per share, with a total value of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The stock was purchased at an average price of $9.33 per share, with a total value of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost bought 23,100 shares of Opko Health stock. The stock was purchased at an average price of $9.22 per share, with a total value of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.48 per share, with a total value of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.49 per share, with a total value of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost bought 11,800 shares of Opko Health stock. The stock was purchased at an average price of $9.43 per share, with a total value of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.46 per share, with a total value of $94,600.00.
  • On Thursday, October 27th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.36 per share, with a total value of $93,600.00.

Opko Health Inc. (NASDAQ:OPK) traded down 1.44% during mid-day trading on Tuesday, hitting $10.29. 540,657 shares of the company’s stock were exchanged. Opko Health Inc. has a 12 month low of $7.12 and a 12 month high of $11.85. The stock’s 50 day moving average price is $9.77 and its 200-day moving average price is $9.86. The stock’s market cap is $5.74 billion.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). The company had revenue of $298 million for the quarter, compared to analysts’ expectations of $322 million. Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. Opko Health’s revenue was up 108.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.25 EPS. Equities analysts expect that Opko Health Inc. will post ($0.08) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Several hedge funds have recently made changes to their positions in OPK. LPL Financial LLC boosted its stake in Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock valued at $142,000 after buying an additional 504 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new stake in Opko Health during the third quarter valued at about $622,000. Whalerock Point Partners LLC purchased a new stake in Opko Health during the third quarter valued at about $2,100,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock valued at $10,038,000 after buying an additional 28,700 shares in the last quarter. Institutional investors own 20.33% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 19th. Jefferies Group reiterated a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Opko Health in a research report on Monday, October 10th. Finally, JPMorgan Chase & Co. set a $14.00 price target on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. Opko Health presently has a consensus rating of “Hold” and a consensus target price of $13.17.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.